Cervomed Inc (CRVO)

$2.65 0.00 (N/A)
Market Cap 39.76M
Revenue (ttm) 4.01M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -672.57%
Debt to Equity Ratio 0.00
Volume 93,000
Avg Vol 7,054,316
Day's Range N/A - N/A
Shares Out 15.12M
Stochastic %K 22%
Beta -0.63
Analysts Strong Sell
Price Target $18.43

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
LetMeGetThatDip
LetMeGetThatDip Aug. 26 at 6:45 PM
$CRVO CervoMed here's my takeaway. • In May 2026, management stated the planned DLB Phase 3 trial was ready and targeted for 2H26, subject to financing. • In June 2026, CRVO publicly announced that securing a strategic partner for Phase 3 became the company's primary objective. • In August 2026, management reiterated that partnering remains the primary goal and stated recent financings extended runway into approximately Q3 2027. • Director Joshua Boger invested approximately $3M in June 2026 and other insiders also participated in financings and purchases.
1 · Reply
BPler
BPler Aug. 26 at 5:57 PM
$CRVO In August 2026, CervoMed announced that neflamapimod received Innovation Passport designation under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB), supporting accelerated development and regulatory engagement https://www.openpr.com/news/4614348/lewy-body-disease-pipeline-shows-strong-momentum-as-15-pharma
0 · Reply
generaltom
generaltom Aug. 26 at 2:49 PM
$CRVO added here too. Valuation seems way too low here when management have been so clear about partnership discussions. Seeing as this spiked above 7 dollars on the news the CEO and board had put their own cash in to look for partners you can imagine the increase if and when a partner is actually announced which will most likely be within months.
1 · Reply
David_M_
David_M_ Aug. 26 at 2:31 PM
$CRVO Added
0 · Reply
Spindr88
Spindr88 Aug. 26 at 1:01 PM
$CRVO red again lol, how many weeks, months is that… turd
0 · Reply
Spindr88
Spindr88 Aug. 26 at 2:20 AM
$CRVO look at the 1yr, 6m, 3m charts… y’all are smoking something. Much (much) better places to invest your capital imo.
2 · Reply
Bearbull_Baggins
Bearbull_Baggins Aug. 25 at 1:27 PM
$CRVO Entered here at 2.61 yesterday. Would like to add more before this takes off, this market cap doesn't seem like a fair valuation for what they may have in their pipeline.
2 · Reply
BPler
BPler Aug. 25 at 10:01 AM
$CRVO Between 31 August and 4 September, Alzheimer Europe will hold an exhibition in the European Parliament to raise awareness of dementia and call on European decision-makers to prioritise dementia as a greater policy matter at EU level. https://www.alzheimer-europe.org/news/alzheimer-europe-aims-raise-profile-dementia-european-parliament-exhibition?language_content_entity=en
1 · Reply
BPler
BPler Aug. 25 at 7:06 AM
$CRVO Cervomed will also take part https://markets.businessinsider.com/news/currencies/public-healthcare-firms-meet-institutional-investors-at-5th-annual-roth-healthcare-opportunities-conference-1036487499
0 · Reply
BPler
BPler Aug. 24 at 1:02 PM
$CRVO Not news, but maybe a good share for those who can't relate to the diseas LBD, betting, working and hoping against this company and their drug Neflamapimod. In the comments are a lot of recent replies and personal stories https://www.facebook.com/share/p/1EkiJ2ggtz/
0 · Reply
Latest News on CRVO
CervoMed price target lowered to $7 from $9 at Roth Capital

2026-08-20T10:40:11.000Z - 6 days ago

CervoMed price target lowered to $7 from $9 at Roth Capital

CervoMed Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 11:30 AM EDT - 15 days ago

CervoMed Transcript: Canaccord Genuity's 46th Annual Growth Conference

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Aug 10, 2026, 7:30 AM EDT - 16 days ago

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed price target lowered to $18 from $27 at Canaccord

2026-08-10T11:05:44.000Z - 16 days ago

CervoMed price target lowered to $18 from $27 at Canaccord

CervoMed Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 19 days ago

CervoMed Quarterly report: Q2 2026

CervoMed Earnings release: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 19 days ago

CervoMed Earnings release: Q2 2026

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

Aug 5, 2026, 7:30 AM EDT - 21 days ago

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Aug 4, 2026, 5:15 AM EDT - 22 days ago

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

Jul 14, 2026, 7:30 AM EDT - 6 weeks ago

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

CervoMed completes enrollment in neflamapimod study

2026-07-09T11:40:46.000Z - 6 weeks ago

CervoMed completes enrollment in neflamapimod study

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Jul 9, 2026, 7:30 AM EDT - 6 weeks ago

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

CervoMed registers to sell 10.08M shares of common stock for holders

2026-07-06T21:05:17.000Z - 7 weeks ago

CervoMed registers to sell 10.08M shares of common stock for holders

CervoMed Registration statement: Registration filing

Jul 6, 2026, 8:00 AM EDT - 7 weeks ago

CervoMed Registration statement: Registration filing

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

Jul 6, 2026, 7:30 AM EDT - 7 weeks ago

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Jun 22, 2026, 4:05 PM EDT - 2 months ago

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CervoMed announces $10M registered direct offering priced at-the-market

2026-06-18T16:40:10.000Z - 2 months ago

CervoMed announces $10M registered direct offering priced at-the-market

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Jun 18, 2026, 12:35 PM EDT - 2 months ago

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CervoMed receives notice of allowance from USPTO on neflamapimod

2026-06-18T11:11:15.000Z - 2 months ago

CervoMed receives notice of allowance from USPTO on neflamapimod

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

Jun 18, 2026, 7:00 AM EDT - 2 months ago

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

CervoMed Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 15, 2026, 7:00 AM EDT - 2 months ago

CervoMed Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

CervoMed Slides: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 15, 2026, 7:00 AM EDT - 2 months ago

CervoMed Slides: 7th Annual HCW Neuro Perspectives Hybrid Conference

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Jun 12, 2026, 7:30 AM EDT - 2 months ago

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

CervoMed announces $10.5M private placement

2026-06-10T11:44:51.000Z - 2 months ago

CervoMed announces $10.5M private placement

CervoMed announces $10.5M private placement

2026-06-10T11:41:14.000Z - 2 months ago

CervoMed announces $10.5M private placement

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

Jun 10, 2026, 7:30 AM EDT - 2 months ago

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

CervoMed Slides: Corporate presentation

Jun 10, 2026, 7:00 AM EDT - 2 months ago

CervoMed Slides: Corporate presentation

CervoMed price target lowered to $9 from $11 at Roth Capital

2026-05-18T21:35:08.000Z - 3 months ago

CervoMed price target lowered to $9 from $11 at Roth Capital

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 18, 2026, 7:30 AM EDT - 3 months ago

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Quarterly report: Q1 2026

CervoMed Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

CervoMed Earnings release: Q1 2026

CervoMed Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

CervoMed Proxy statement: Proxy filing

CervoMed presents neflamapimod MRI data

2026-04-22T14:32:59.000Z - 4 months ago

CervoMed presents neflamapimod MRI data

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

Apr 22, 2026, 7:30 AM EDT - 4 months ago

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

Apr 7, 2026, 7:30 AM EDT - 5 months ago

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Transcript: The 38th Annual Roth Conference

CervoMed Slides: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 months ago

CervoMed Slides: The 38th Annual Roth Conference

CervoMed’s neflamapimod shows efficacy in dementia with DLB

2026-03-19T11:56:17.000Z - 5 months ago

CervoMed’s neflamapimod shows efficacy in dementia with DLB

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology

Mar 19, 2026, 7:30 AM EDT - 5 months ago

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology

CervoMed price target lowered to $11 from $19 at Roth Capital

2026-03-17T23:00:26.000Z - 5 months ago

CervoMed price target lowered to $11 from $19 at Roth Capital

CervoMed price target raised to $21 from $15 at Chardan

2026-03-17T22:25:46.000Z - 5 months ago

CervoMed price target raised to $21 from $15 at Chardan

CervoMed Earnings release: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Earnings release: Q4 2025

CervoMed Annual report: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 5 months ago

CervoMed Annual report: Q4 2025

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

2026-03-17T11:46:53.000Z - 5 months ago

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Mar 17, 2026, 7:30 AM EDT - 5 months ago

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

CervoMed Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

CervoMed Slides: Corporate presentation

CervoMed announces presentations at AP/PD 2026 scientific conference

2026-03-12T11:27:04.000Z - 5 months ago

CervoMed announces presentations at AP/PD 2026 scientific conference

CervoMed completes Phase 1 volunteer study for neflamapimod

2026-03-04T12:41:24.000Z - 6 months ago

CervoMed completes Phase 1 volunteer study for neflamapimod

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Mar 4, 2026, 7:30 AM EST - 6 months ago

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform

2026-02-18T11:16:19.000Z - 6 months ago

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Feb 17, 2026, 8:00 AM EST - 6 months ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SCYX

CervoMed initiated with an Overweight at Cantor Fitzgerald

2025-12-18T11:40:57.000Z - 8 months ago

CervoMed initiated with an Overweight at Cantor Fitzgerald

CervoMed’s neflamapimod shows efficacy in slowing dementia

2025-12-04T22:05:45.000Z - 9 months ago

CervoMed’s neflamapimod shows efficacy in slowing dementia

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 4, 2025, 5:00 PM EST - 9 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Dec 2, 2025, 7:00 AM EST - 9 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 24, 2025, 7:00 AM EST - 9 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

CervoMed Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

CervoMed Earnings release: Q3 2025

CervoMed Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

CervoMed Quarterly report: Q3 2025

CervoMed Transcript: Emerging Growth Conference

Oct 22, 2025, 11:25 AM EDT - 11 months ago

CervoMed Transcript: Emerging Growth Conference

CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 11 months ago

CervoMed to Present at the Emerging Growth Conference

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 8, 2025, 7:00 AM EDT - 11 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 2, 2025, 8:00 AM EDT - 11 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 17, 2025, 7:30 AM EDT - 1 year ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

CervoMed Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 2:00 PM EDT - 1 year ago

CervoMed Transcript: H.C. Wainwright 27th Annual Global Investment Conference

CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 1 year ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Earnings release: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q2 2025

CervoMed Quarterly report: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 1 year ago

CervoMed Quarterly report: Q2 2025

CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Transcript: Status Update

CervoMed Press release: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Press release: Status Update

CervoMed Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Status Update

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

Jul 8, 2025, 7:00 AM EDT - 1 year ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

CervoMed Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation

CervoMed Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation

CervoMed Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 5:00 PM EDT - 1 year ago

CervoMed Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

CervoMed Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Earnings release: Q1 2025

CervoMed Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Quarterly report: Q1 2025

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 12, 2025, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

CervoMed Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CervoMed Proxy statement: Proxy Filing

CervoMed Slides: Investor Presentation

Apr 5, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

CervoMed Earnings release: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q4 2024

CervoMed Annual report: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Annual report: Q4 2024

CervoMed Slides: Investor Presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

CervoMed Slides: Investor Presentation

Jan 31, 2025, 7:00 AM EST - 1 year ago

CervoMed Slides: Investor Presentation

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Quarterly report: Q3 2024

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 6, 2024, 1:50 PM EDT - 2 years ago

CervoMed Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Aug 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 12:30 PM EDT - 2 years ago

CervoMed Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

CervoMed Quarterly report: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q2 2024

CervoMed Earnings release: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 2 years ago

CervoMed Earnings release: Q2 2024

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

CervoMed Transcript: Status Update

Jul 23, 2024, 10:00 AM EDT - 2 years ago

CervoMed Transcript: Status Update

CervoMed Slides: Corporate Presentation

Jul 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Slides: Corporate Presentation

CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in the Emerging Growth Conference

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jul 11, 2024, 8:51 AM EDT - 2 years ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

Jun 11, 2024, 8:00 AM EDT - 2 years ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed Registration statement: Registration Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Quarterly report: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q1 2024

CervoMed Earnings release: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Earnings release: Q1 2024

CervoMed Registration statement: Registration Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

CervoMed Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

CervoMed Proxy statement: Proxy Filing

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

LetMeGetThatDip
LetMeGetThatDip Aug. 26 at 6:45 PM
$CRVO CervoMed here's my takeaway. • In May 2026, management stated the planned DLB Phase 3 trial was ready and targeted for 2H26, subject to financing. • In June 2026, CRVO publicly announced that securing a strategic partner for Phase 3 became the company's primary objective. • In August 2026, management reiterated that partnering remains the primary goal and stated recent financings extended runway into approximately Q3 2027. • Director Joshua Boger invested approximately $3M in June 2026 and other insiders also participated in financings and purchases.
1 · Reply
BPler
BPler Aug. 26 at 5:57 PM
$CRVO In August 2026, CervoMed announced that neflamapimod received Innovation Passport designation under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB), supporting accelerated development and regulatory engagement https://www.openpr.com/news/4614348/lewy-body-disease-pipeline-shows-strong-momentum-as-15-pharma
0 · Reply
generaltom
generaltom Aug. 26 at 2:49 PM
$CRVO added here too. Valuation seems way too low here when management have been so clear about partnership discussions. Seeing as this spiked above 7 dollars on the news the CEO and board had put their own cash in to look for partners you can imagine the increase if and when a partner is actually announced which will most likely be within months.
1 · Reply
David_M_
David_M_ Aug. 26 at 2:31 PM
$CRVO Added
0 · Reply
Spindr88
Spindr88 Aug. 26 at 1:01 PM
$CRVO red again lol, how many weeks, months is that… turd
0 · Reply
Spindr88
Spindr88 Aug. 26 at 2:20 AM
$CRVO look at the 1yr, 6m, 3m charts… y’all are smoking something. Much (much) better places to invest your capital imo.
2 · Reply
Bearbull_Baggins
Bearbull_Baggins Aug. 25 at 1:27 PM
$CRVO Entered here at 2.61 yesterday. Would like to add more before this takes off, this market cap doesn't seem like a fair valuation for what they may have in their pipeline.
2 · Reply
BPler
BPler Aug. 25 at 10:01 AM
$CRVO Between 31 August and 4 September, Alzheimer Europe will hold an exhibition in the European Parliament to raise awareness of dementia and call on European decision-makers to prioritise dementia as a greater policy matter at EU level. https://www.alzheimer-europe.org/news/alzheimer-europe-aims-raise-profile-dementia-european-parliament-exhibition?language_content_entity=en
1 · Reply
BPler
BPler Aug. 25 at 7:06 AM
$CRVO Cervomed will also take part https://markets.businessinsider.com/news/currencies/public-healthcare-firms-meet-institutional-investors-at-5th-annual-roth-healthcare-opportunities-conference-1036487499
0 · Reply
BPler
BPler Aug. 24 at 1:02 PM
$CRVO Not news, but maybe a good share for those who can't relate to the diseas LBD, betting, working and hoping against this company and their drug Neflamapimod. In the comments are a lot of recent replies and personal stories https://www.facebook.com/share/p/1EkiJ2ggtz/
0 · Reply
BPler
BPler Aug. 23 at 8:56 PM
$CRVO Not sure it was posted already but it popped up as posted today https://www.lewybody.org/step-towards-lewy-body-dementia-treatment/
0 · Reply
walker7782
walker7782 Aug. 22 at 1:16 AM
$CRVO Added 2.50 - 2.59 Glad I had a buy order in at 2.50!
0 · Reply
K4mpas
K4mpas Aug. 21 at 8:31 PM
$CRVO Buy again and again you will remember me and thanks me later🚀
2 · Reply
David_M_
David_M_ Aug. 21 at 5:29 PM
$CRVO
0 · Reply
Houseofsweeps
Houseofsweeps Aug. 21 at 2:37 PM
$CRVO real quiet in here. This thing will move when the partnership comes in big. Problem is it could be anytime. It could be next week it could be in 2 months. I think they will make the right move ‼️
3 · Reply
K4mpas
K4mpas Aug. 21 at 9:45 AM
$CRVO ready for good news next week?🚀
1 · Reply
BPler
BPler Aug. 21 at 6:44 AM
$CRVO The longer it takes to figure out a partnership, the more I wonder: Could regional licensing be the preferred mechanism to fund the Phase 3 DLB trial to keep insider shareholder value up? The Strategy: Management is reviewing multiple partnership formats. Selling Ex-U.S. regional rights while keeping the U.S. market is a standard biotech model. Patent US: Market protections until 2042 already secured (maybe why we went up?) The Funding Model: A regional deal with a European pharma company could bring in upfront cash and development cost-sharing to fund Phase 3 global trial expenses. The Regulatory Angle: Management aligned with the EMA on a registration path. Adding an EMA PRIME designation to their UK Innovation Passport could boost the value of those European rights. https://www.investing.com/news/transcripts/cervomed-at-canaccord-genuity-conference-dlb-push-gains-ground-93CH-4852557
0 · Reply
K4mpas
K4mpas Aug. 21 at 5:28 AM
$CRVO Partnetship coming soon… Don’t wait the pump,that will be too late !!
1 · Reply
Spindr88
Spindr88 Aug. 20 at 7:38 PM
$CRVO people smoking stuff here again.
0 · Reply
Stu_padasso
Stu_padasso Aug. 20 at 7:18 PM
$CRVO well its going to be a long wait lol
1 · Reply
K4mpas
K4mpas Aug. 20 at 5:24 PM
$CRVO the best sport 2.6 now to buy this is the finally chance,next stop 5->10->25 and then too late..Buy buy buy 🚀
0 · Reply
BPler
BPler Aug. 20 at 11:44 AM
$CRVO Preprint for Alzheimer's Research & Therapy Journal https://www.researchsquare.com/article/rs-10623740/v1
0 · Reply